Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ORIG3N
company
About
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
- 11 - 50
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Health Care,Medical,Personal Health
- Founded date
- Apr 10, 2014
- Number Of Employee
- 11 - 50
- Operating Status
- Active
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications.It was founded in 2014 and is based in Boston, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$46.90M
ORIG3N has raised a total of
$46.90M
in funding over 2 rounds. Their latest funding was raised on
Jul 12, 2018 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 12, 2018 | Series B | $14.40M | 2 | — | — | Detail |
| Jun 27, 2017 | Series Unknown | $20M | 3 | — | — | Detail |
| Dec 12, 2015 | Series A | $12.50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
4
ORIG3N is funded by 4 investors.
LabCorp
and MMIC Investment Holdings
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
LabCorp
|
— | Series B |
|
|
— | Series B |
|
|
— | Series Unknown |
|
|
— | Series Unknown |
Acquisition
ORIG3N has acquired 1 organizations. Their most recent acquisition was Interleukin Genetics on Nov 22, 2017. They acquired Interleukin Genetics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Nov 22, 2017
Interleukin Genetics
|
Biotechnology | acquisition | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
